For context, heres how the most recent GLP-1 weight-loss drugs reached UK patients: Wegovy (semaglutide 2.4 mg): MHRA approval September 2021, NICE TA875 issued March 2023
Most people start seeing results within the first month, with the biggest weight loss happening over several months
Semaglutide can interact with certain drugs, particularly those that also affect blood sugar, like insulin or sulfonylureas
This dual action makes tirzepatide unique and often more potent
In return for the license, Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program
Clinical data shows that weekly schedules produce more stable weight loss outcomes than extended intervals